Post hoc analyses of East Asian patients from the randomized placebo-controlled PREVAIL trial of enzalutamide in patients with chemotherapy-naïve, metastatic castration-resistant prostate cancer

Enzalutamide is an androgen receptor (AR) inhibitor that acts on different steps in the AR signaling pathway. In PREVAIL, an international, phase III, double-blind, placebo-controlled trial, enzalutamide significantly reduced the risk of radiographic progression by 81% (hazard ratio [HR], 0.19; P

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Medicine (Baltimore) 2017-07, Vol.96 (27), p.e7223-e7223
Hauptverfasser:	Kim, Choung Soo, Choi, Young Deuk, Lee, Sang Eun, Lee, Hyun Moo, Ueda, Takeshi, Yonese, Junji, Fukagai, Takashi, Chiong, Edmund, Lau, Weber, Abhyankar, Sarang, Theeuwes, Ad, Tombal, Bertrand, Beer, Tomasz M., Kimura, Go
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Antineoplastic Agents - adverse effects Antineoplastic Agents - blood Antineoplastic Agents - therapeutic use Biomarkers, Tumor - metabolism Clinical Trial/Experimental Study Disease-Free Survival Double-Blind Method Follow-Up Studies Humans Japan Male Middle Aged Phenylthiohydantoin - adverse effects Phenylthiohydantoin - analogs & derivatives Phenylthiohydantoin - blood Phenylthiohydantoin - therapeutic use Proportional Hazards Models Prostate-Specific Antigen Prostatic Neoplasms, Castration-Resistant - diagnostic imaging Prostatic Neoplasms, Castration-Resistant - drug therapy Prostatic Neoplasms, Castration-Resistant - metabolism Republic of Korea Risk Singapore Time Factors Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Enzalutamide is an androgen receptor (AR) inhibitor that acts on different steps in the AR signaling pathway. In PREVAIL, an international, phase III, double-blind, placebo-controlled trial, enzalutamide significantly reduced the risk of radiographic progression by 81% (hazard ratio [HR], 0.19; P
ISSN:	0025-7974 1536-5964
DOI:	10.1097/MD.0000000000007223